Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?

Oct 19 2016

• By Brenda Sandburg

Related Content

Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back

Oct 18 2016

Inflectra Launch Prep Continues Post-Deadline, Pfizer Says

Oct 06 2016

Pfizer Eliminates Roadblock To Remicade Biosimilar Launch

Aug 17 2016

Rise Of The Biosimilar Formulary: CVS Excludes Lantus, Neupogen For 2017

Aug 03 2016

Related Companies

Celltrion, Inc.

Pfizer Inc.

Johnson & Johnson

Apotex Inc.

Novartis AG

Amgen, Inc.

Additional Topics

United States Biosimilars Legal Issues Policy BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window